The effect of Xolair (omalizumab) on inhibiting leukotriene and cytokine (IL-4 and IL-13) release from blood basophils.
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2013
At a glance
- Drugs Omalizumab (Primary)
- Indications Seasonal allergic rhinitis
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jul 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.